Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines

Vaccine

Volumn 30, Issue 35, 2012, Pages 5215-5221

  Monsonego, Joseph ^a   Zerat, Laurent ^b   Syrjänen, Kari ^c   Zerat, Jean Claude ^b   Smith, Jennifer S ^d   Halfon, Philippe ^e  

^a Institut du Col   (France)

^b Laboratoire Lavergne   (France)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d University of North Carolina at Chapel Hill   (United States)

^e Alphabio CDL   (France)

Author keywords

Cytological screening; France; HPV prevalence; Human papillomavirus; Vaccination

Indexed keywords

MESSENGER RNA; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE OR GREATER; CIGARETTE SMOKING; COLPOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRANCE; GENOTYPE; GROUPS BY AGE; GYNECOLOGICAL EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCREENING TEST; SEXUALITY; SQUAMOUS CELL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS;

ADULT; AGED; BIOPSY; CERVIX UTERI; COLPOSCOPY; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; FRANCE; GENOTYPE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84863826994     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.013     Document Type: Article

References (43)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr.
2. De Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
3. De Vuyst H., Clifford G., Li N., Franceschi S. HPV infection in Europe. Eur J Cancer 2009, 45:2632-2639.
4. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632.
5. Institut National du Cancer Le cancer du col de l'uterus en France. Etat des lieux en 2010 2010, Available from: http://www.e-cancer.fr/prevention/environnement-et-cancers/agents-infectieux/.
6. Monsonego J., Hudgens M.G., Zerat L., Zerat J.-C., Syrjänen K., Halfon P., et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011, 129:691-701.
7. Dockter J., Schroder A., Eaton B., Wang A., Sikhamsay N., Morales L., et al. Analytical characterization of the APTIMA HPV assay. J Clin Virol 2009, 45:S39-S47.
8. Clavel C., Masure M., Bory J.-P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001, 84:1616-1623.
9. Pista A., de Oliveira C.F., Cunha M.J., Paixao M.T., Real O. Prevalence of human papillomavirus infection in women in Portugal: the CLEOPATRE Portugal study. Int J Gynecol Cancer 2011, 21:1150-1158. CLEOPATRE Portugal Study Group.
10. Dunne E.F., Unger E.R., Sternberg M., McQuillan G., Swan D.C., Patel S.S., et al. Prevalence of HPV infection among females in the United States. JAMA 2007, 297:813-819.
11. Iftner T., Eberle S., Iftner A., Holz B., Banik N., Quint W., et al. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30years of age: an epidemiological observational study. J Med Virol 2010, 82:1928-1939.
12. Kjaer S.K., Breugelmans G., Munk C., Junge J., Watson M., Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008, 123:1864-1870.
13. Smith J.S., Melendy A., Rana R.K., Pimenta J.M. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008, 43:S5-S25.
14. Chaturvedi A.K., Katki H.A., Hildesheim A., Rodríguez A.C., Quint W., Schiffman M., et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical cancer. J Infect Dis 2011, 203:910-920.
15. Smith J.S., Melendy A., Rana R.K., Pimenta J.M. Age-specific prevalence of human papillomavirus infection in females: a global review. J Adolesc Health 2008, 43. S5-25, S25.e1-41.
16. Coupé V.M., Berkhof J., Bulkmans N.W., Snijders P.J., Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98:646-651.
17. De Sanjosé S., Diaz M., Castellsagué X., Clifford G., Bruni L., Muñoz N., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
18. Ammatuna P., Giovannelli L., Matranga D., Ciriminna S., Perino A. Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, South Italy. Cancer Epidemiol Biomarkers Prev 2008, 17:2002-2006.
19. Karlsson R., Jonsson M., Edlund K., Evander M., Gustavsson A., Bodén E., et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex Transm Dis 1995, 22:119-127.
20. Vaccarella S., Franceschi S., Herrero R., Muñoz N., Snijders P.J., Clifford G.M., et al. Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev 2006, 15:326-333.
21. Confortini M., Carozzi F., Zappa M., Ventura L., Iossa A., Cariaggi P., et al. Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitment. BMC Infect Dis 2010, 10:157.
22. Kocken M., Helmerhorst T.J., Berkhof J., Louwers J.A., Nobbenhuis M.A., Bais A.G., et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011, 12:441-450.
23. Joura E, Paavonen J, Ferris D, Sings HL, James M, Haupt RM. Impact of Gardasil® in women who have undergone definitive therapy. Abstract and poster presented at the 16th international meeting of the European society of gynaecological oncology, Belgrade, Serbia; 11-14 October 2009.
24. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009, 5:696-704.
25. Garland S.M., Smith J.S. Human papillomavirus vaccines: current status and future prospects. Drugs 2010, 70:1079-1098.
26. Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006, 24:S3:78-89.
27. Leinonen M., Nieminen P., Kotaniemi-Talonen L., Malila N., Tarkkanen J., Laurila P., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009, 101:1612-1623.
28. Meijer C.J., Berkhof J., Castle P.E., Hesselink A.T., Franco E.L., Ronco G., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30years and older. Int J Cancer 2009, 124:516-520.
29. Franco E.L. A new generation of studies of human papillomavirus DNA testing in cervical cancer screening. J Natl Cancer Inst 2009, 101:1600-1601.
30. Castle P.E., Stoler M.H., Wright T.C., Sharma A., Wright T.L., Behrens C.M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011, 12:880-890.
31. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
32. Franceschi S., Denny L., Irwin K.L., Jeronimo J., Lopalco P.L., Monsonego J., et al. EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer 2011, 128:2765-2774.
33. Sargent A., Bailey A., Almonte M., Turner A., Thomson C., Peto J., et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008, 98:1701-1709.
34. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16-26years. J Infect Dis 2009, 199:926-935.
35. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26years. J Infect Dis 2009, 199:936-944.
36. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009, 199:919-922.
37. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
38. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.-N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
39. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
40. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
41. GlaxoSmithKline Clinical Study Register. Studies 580299/001 and 580299/007. Available at: [accessed 24.11.11]. http://download.gsk-clinicalstudyregister.com/files/20401.pdf.
42. Winer R.L., Hughes J.P., Feng Q., Xi L.F., Cherne S., O'Reilly S., et al. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 2011, 20:699-707.
43. Hesselink A.T., Heideman D.A., Berkhof J., Topal F., Pol R.P., Meijer C.J., et al. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening. J Clin Microbiol 2010, 48:797-801.